Oncology Activities

New and Emerging Treatments for the Care of Patients with EGFR– and ALK–Positive NSCLC

0290-0000-18-082-L01-P

1.00

The Role of the Clinical Pharmacist in Reducing the Clinical Impact of Prostate Cancer: New and Emerging Therapy Options

0290-0000-18-055-H01-P

This activity will review incidence of disease and risk factors in prostate cancer and emphasize communication between patients and healthcare professionals.

1.50

Exploring Treatment Options for Patients with Acute Lymphoblastic Leukemia (ALL)

0290-0000-18-068-L01-P

1.00

Recent Advances in the Care of Patients with Chronic Lymphocytic Leukemia (CLL)

0290-0000-18-067-H01-P

Over the past decade, the number of therapeutic options for CLL have increased. This activity will discuss new CLL treatment options and their place in therapy

2.00

New Options in the Management of Chemotherapy–Induced Nausea and Vomiting

0290-0000-18-056-H01-P

This symposium highlights recent advances in the pharmacologic management of CINV and provide practical guidance on the appropriate, patient-specific therapy.

1.50

An American Journal of Managed Care Supplement: Managing the Evolving Landscape of Metastatic Colorectal Cancer (mCRC) Treatment Options

0290-0000-18-035-H01-P

This supplement was constructed with the goal of providing managed care pharmacists with an understanding of treatment options for colorectal cancer.

2.00

Recent Advances in Cancer Immunotherapy

0290-0000-17-196-H01-P

This activity will focus on available immunotherapy agents and approaches to ensure access and adherence to newly approved immunotherapy-based treatments.

1.00

Optimizing Patient Management in Lung Cancer

0290-0000-17-202-H01-P

With this PTCE program, the current available treatment approaches, including systemic and novel treatments, in lung cancer therapy will be analyzed.

1.00